A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-Release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aspirin/dipyridamole (Primary) ; Aspirin
Indications Coronary artery disease; Embolism and thrombosis
Focus Pharmacodynamics
Sponsors Boehringer Ingelheim

Most Recent Events

07 Jan 2009 Planned number of patients changed from 22 to 11 as reported by ClinicalTrials.gov.
09 May 2008 Status changed from in progress to completed.
15 Nov 2007 Trial centre added.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight